Drug intelligence / Profile preview

salvigenin

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral

Overview

Salvigenin is a natural trimethoxylated flavone found in medicinal plants such as *Scutellariae Barbatae Herba* and *Scutellariae Radix*. It exhibits significant anti-tumor activity, particularly in hepatocellular carcinoma (HCC) and colon cancer. Its mechanism of action involves the inhibition of the PI3K/AKT/GSK-3β signaling pathway, which leads to the suppression of aerobic glycolysis (the Warburg effect) by reducing glucose uptake and lactate production. Additionally, salvigenin has been shown to sensitize cancer cells to chemotherapy agents like 5-fluorouracil (5-FU) and induce apoptosis in both in-vitro and in-vivo models.

Other names: 5-hydroxy-6,7,4'-trimethoxyflavonesalvigenin

Targets

AKT (RAC-alpha serine/threonine-protein kinase)GSK3 (Glycogen synthase kinase 3 beta)PI3K (Phosphoinositide-3-kinase regulatory subunit 6)

Beyond the preview

Go deeper on salvigenin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on salvigenin.

Explore the full profile